AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
First National's 15min chart shows KDJ Death Cross, Bearish Marubozu pattern.
ByAinvest
Thursday, Oct 16, 2025 3:18 pm ET1min read
The 15-minute chart of First National's stock price triggered a KDJ Death Cross and a bearish Marubozu at 10:15 AM EST on October 16, 2025. This indicates that the momentum of the stock price is shifting towards the downside and has the potential to further decrease, with sellers dominating the market. The bearish momentum is likely to continue.
Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company, recently reported its third quarter 2025 financial results and announced a significant divestment plan for its migraine and inhalation assets. The company also provided an update on its merger with Cullgen, which is expected to close in the near future.# Financial Performance
The company reported zero revenue in Q3 2025, a significant decrease from $1.6 million in Q2 2025. Research and development (R&D) expenses were reduced to under $0.1 million from $2.8 million year-over-year. The cash position as of September 30, 2025, stood at $5.8 million, providing sufficient funding for operations through the merger closing.
# Divestment Plan
Pulmatrix has announced a divestment plan for its migraine and inhalation assets, including the proprietary iSPERSE™ technology and three clinical programs. This move is part of the company's strategic merger with Cullgen, which aims to create a Nasdaq-listed company focused on targeted protein degradation therapies. The merger, approved by stockholders on June 16, 2025, awaits approval from Nasdaq and the China Security Regulatory Commission.
# Merger Details
The merger with Cullgen is expected to close in the near future, creating a combined entity with approximately $65 million in cash. Post-merger, the new company will focus on targeted protein degrader therapies with three Phase 1 clinical programs. Pulmatrix's cash position of $5.8 million as of June 30, 2025, is expected to fund operations through the merger closing.
# Market Implications
The financial results and the divestment plan indicate a strategic shift for Pulmatrix, focusing on targeted protein degradation therapies. The bearish market signals, including the KDJ Death Cross and bearish Marubozu, suggest that the momentum of the stock price is shifting towards the downside, with sellers dominating the market. Investors should closely monitor the merger progress and the company's financial performance in the coming quarters.
References
- Pulmatrix Stock Price, News & Analysis: `
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet